TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02095132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given PO
Study: NCT04482985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meclizine Hydrochloride
Description: Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meclizine Hydrochloride
Description: Meclzine is given to all study participants to prevent seasickness. Meclizine plasma levels are determined from both the meclizine responders and non responders group.
Study: NCT01625533

Intervention type: PROCEDURE
Intervention: Standard Coronary Angiography
Description: Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.

Intervention type: PROCEDURE
Intervention: Dual-axis Rotational Coronary Angiography
Description: Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
Study: NCT04501029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Description: Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.
Study: NCT02518503

Intervention type: DRUG
Intervention: Rosuvastatin (≥10 mg)
Description: Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Atorvastatin (≥20 mg)
Description: Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Simvastatin (≥40 mg)
Description: Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Fluvastatin
Description: Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Pravastatin
Description: Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Lovastatin
Description: Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Rosuvastatin (<10mg)
Description: Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for \<10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Atorvastatin (<20mg)
Description: Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).

Intervention type: DRUG
Intervention: Simvastatin (<40 mg)
Description: Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT03800472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3312 IR
Description: GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
Study: NCT02711137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Standard of Care (SOC) agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Standard of Care (SOC) agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Standard of Care (SOC) agents
Study: NCT03800472

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3312 MR
Description: GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3312 FE MR
Description: GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3312 MR
Description: GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3312 MR
Description: GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo optimized tablets
Study: NCT03255070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: An antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: An antibody drug conjugate
Study: NCT03528525

Intervention type: OTHER
Description: observation
Study: NCT01544088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Treatment (GCBT)
Description: GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Group Treatment
Description: The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
Study: NCT02542930

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
Study: NCT00470613

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-53
Description: For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
Study: NCT04675879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder arm bandage
Description: Three different shoulder-arm bandage types

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder arm bandage
Description: Three different shoulder-arm bandage types

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder arm bandage
Description: Three different shoulder-arm bandage types
Study: NCT03882099

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of Vitamin D by ELISA
Description: Blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of Vitamin D by ELISA
Description: Blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of Vitamin D by ELISA
Description: Blood samples
Study: NCT00639093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational / motivational combined with crushing
Description: All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer).
Study: NCT04018365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Tablets
Description: The administration is oral administration with water before or after breakfast.
Study: NCT01948258

Intervention type: DEVICE
Group type: OTHER
Intervention: Clearblue Advanced Fertility Monitor
Description: Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
Study: NCT02647944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03239314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: Injected in the adductor canal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Injected in the adductor canal
Study: NCT00639093

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducational / motivational combined with control
Description: All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer).
Study: NCT01911676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Study: NCT01415076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insufflation with CO2
Description: Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Insufflation with CO2
Description: Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
Study: NCT02921100

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cytology
Description: The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DNA ploidy
Description: DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-FNA
Description: All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
Study: NCT01911676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03214276

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vinitrox polyphenols
Description: Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
Study: NCT02921100

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-FNA
Description: All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.

Intervention type: DEVICE
Group type: OTHER
Intervention: EUS-guided fine needle

Intervention type: DEVICE
Group type: OTHER
Intervention: EUS-guided fine needle
Study: NCT03214276

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
Study: NCT03194139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 30 mg IV
Description: GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
Study: NCT00908700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical occlusion of the left atrial appendage
Description: Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical practice
Description: Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
Study: NCT06256276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein powder and L-carnitine
Description: Dietary supplement intervention for 16 weeks
Study: NCT03194139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 50 mg IV
Description: GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419 45 mg IV
Description: GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
Study: NCT06256276

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo powder and Psyllium Husk capsules
Description: Maltodextrin placebo powder and Psyllium Husk capsules
Study: NCT03729284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta Capsules
Description: Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride Capsules
Description: Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
Study: NCT04521452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: Subjects will receive evogliptin 5 mg daily
Study: NCT00788333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab (Herceptin®)
Description: IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
Study: NCT00432432

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab and MTX
Description: MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Study: NCT06657469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Functions Training (AFT)
Description: The AFT protocol included 18 group-based sessions, 75 minutes each, administered twice a week over a nine-week period. The training focused on improving sustained attention, selective-spatial attention, and executive attention through computerized tasks like the Conjunctive Continuous Performance Task and Go/No-Go tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Executive Functions Training (EFT)
Description: The EFT protocol included similar session structures with a focus on executive functions such as working memory, cognitive flexibility, and problem-solving. Tasks included computerized games such as visual puzzles.
Study: NCT04176523

Intervention type: DRUG
Intervention: Carglumic Acid
Description: Maintenance therapy with carglumic acid

Intervention type: DRUG
Intervention: Carglumic Acid
Description: Maintenance therapy with carglumic acid
Study: NCT03483753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
Study: NCT04060836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyntha
Description: Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyntha
Description: Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor VIII Injection
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Study: NCT01986530

Intervention type: DIETARY_SUPPLEMENT
Intervention: Boost
Description: After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion

Intervention type: OTHER
Intervention: Aerobic exercise
Description: After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
Study: NCT00289705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Laparoscopic Roux-en-Y gastric bypass
Study: NCT02789696

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis of acromegaly
Description: Biological analysis of IGF-1
Study: NCT04060836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor VIII Injection
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Study: NCT00417222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil
Description: 5 to 40mg P.O. daily until the end of the study
Study: NCT00541229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg tablets q.d. (once daily) for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 200 mg tablets q.d. (once daily) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.